Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane


A Randomized Phase II Open Label Study to Assess the Efficacy & Safety of Gemcitabine + Abraxane® With or Without ODSH (2-0, 3-0 Desulfated Heparin) as First Line Treatment of Metastatic Pancreatic Cancer




The purpose of the study is to determine whether ODSH (2-0,3-0 desulfated heparin), a low anticoagulant heparin derivate with preserved anti-inflammatory and anti-neoplastic characteristics is efficacious in patients with metastatic pancreatic cancer with gemcitabine and nab-paclitaxel ( Abraxane) as first line therapy.

Study Status: Recruiting

Jessica Woodring, MBA, CAPM 954-659-5538

Condition Intervention Phase
Metastatic Pancreatic Cancer Drug: Abraxane ( Nab-paclitaxel)
Drug: Abraxane ( Nab-paclitaxel)
Drug: Gemcitabine
Drug: Gemcitabine
Drug: ODSH ( 2-O, 3-O Desulfated Heparin)
Drug: ODSH ( 2-O, 3-O Desulfated Heparin)
Drug: Abraxane ( nab-paclitaxel)
Drug: Gemcitabine
Phase 2

Verified by ParinGenix November, 2012

Sponsored by: ParinGenix
Information provided by: ParinGenix identifier: NCT01461915

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Florida
Weston, Florida 33331
United States

Mitesh J Borad, MD., Principal Investigator
Stephen Marcus, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site